Phenotypes associated with this allele

• Allele Symbol: Cda^{tm1d(EUCOMM)Wtsi}
• Allele Name: targeted mutation 1d, Wellcome Trust Sanger Institute
• Allele ID: MGI:7442520
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cda^tm1d(EUCOMM)Wtsi/Cda^tm1d(EUCOMM)Wtsi	involves: C57BL/6 * C57BL/6J * C57BL/6N	MGI:7446771

Genotype
MGI:7446771

hm1

• Allelic Composition: Cda^{tm1d(EUCOMM)Wtsi}/Cda^{tm1d(EUCOMM)Wtsi}
• Genetic Background: involves: C57BL/6 * C57BL/6J * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal cell physiology ( J:332259 )

• cultured primary kidney cells show a pyrimidine pool disequilibrium with significantly larger pools of cytidine (C) and deoxycytidine (dC) but no significant accumulation of deoxycytidine triphosphate (dCTP) relative to control kidneys cells

elevated level of mitotic sister chromatid exchange ( J:332259 )

• cultured primary kidney cells show a 6-fold increase in the % of metaphases with > 0.4 SCE per chromosome relative to control kidneys cells

chromosomal instability ( J:332259 )

• cultured primary kidney cells show a significantly higher sister chromatid exchange (SCE) frequency than control kidneys cells (0.33 SCE/chromosome versus 0.24 SCE/chromosome, respectively) and a 6-fold increase in the % of metaphases with > 0.4 SCE per chromosome

• also, the frequency of ultrafine anaphase bridges (UFB) is significantly higher (2.53 UFB/anaphase) than in control kidneys cells (1.41 UFB/anaphase) while the % of anaphase cells with 3 and 4 UFBs is 2.84 and 2.35 times higher than in control kidneys cells

homeostasis/metabolism

abnormal enzyme/coenzyme activity ( J:332259 )

• primary kidney cells show significantly reduced basal Parp1 [poly (ADP-ribose) polymerase family, member 1] activity; basal levels of poly (ADP-ribosyl)ation (i.e. PARylation) are 45% lower than in control cells

decreased incidence of tumors by chemical induction ( J:332259 )

• after azoxymethane (AOM)/dextran sodium sulfate (DSS) treatment, mice of both sexes show significantly fewer colon tumors of > 4 mm in diameter than similarly treated control mice

neoplasm

neoplasm ( J:332259 )

N • untreated old mice exhibit a normal lifespan with no significant differences in the frequency or type of spontaneous tumors relative to control mice

decreased incidence of tumors by chemical induction ( J:332259 )

• after azoxymethane (AOM)/dextran sodium sulfate (DSS) treatment, mice of both sexes show significantly fewer colon tumors of > 4 mm in diameter than similarly treated control mice

decreased tumor growth/size ( J:332259 )

• after azoxymethane (AOM)/dextran sodium sulfate (DSS) treatment, mice of both sexes develop smaller colon tumors than similarly treated control mice

behavior/neurological

behavior/neurological phenotype ( J:332259 )

N • untreated mice show no differences in health or behavior relative to controls over a period of 32 months